RESEARCH · TESAMORELIN · PHARMACOLOGY
Tesamorelin Pharmacology: DPP-4 Resistance, PK/PD Models and Pulsatile GH Release
Tesamorelin (TH9507) is a synthetic analogue of human growth-hormone-releasing factor, GRF(1-44). Our earlier articles cover the overall research picture and the visceral-fat and liver-fat trial series. This article stays with pharmacology: how the molecule was modified, what population pharmacokinetic and pharmacodynamic models describe, and how researchers measured its effect on the pulsatile pattern of growth hormone (GH) secretion. PurixLab’s Tesamorelin 5mg is a research material for laboratory research use only; clinical formulations and protocols are not the same as a research vial.
A single N-terminal modification
Native GRF(1-44) is rapidly inactivated in plasma, largely by dipeptidyl aminopeptidase-IV (DPP-4) cleavage near the N-terminus. The non-clinical characterisation of TH9507 describes an analogue of hGRF(1-44)NH2 minimally modified by adding a trans-3-hexenoyl moiety to Tyr1. That change made the peptide resistant to DPP-4 deactivation, slowed its in vitro degradation in rat, dog and human plasma compared with the natural sequence, and prolonged plasma elimination of immunoreactive TH9507 in vivo [1]. Repeated administration in pigs, rats and dogs markedly raised plasma GH and insulin-like growth factor-1 (IGF-1), and subchronic studies in rats and dogs of up to 4 months reported increased body-weight gain associated with the biomarker response [1]. Reviews written around the 2010 US approval describe the same core idea: the molecule stimulates synthesis and release of endogenous GH rather than supplying GH itself [2,3].
Population pharmacokinetics
González-Sales and colleagues pooled Phase 1 data from 38 HIV-infected patients and healthy subjects who received subcutaneous tesamorelin (1 or 2 mg daily) for 14 consecutive days. An open one-compartment model with first- and zero-order absorption and first-order elimination best described the data. Plasma clearance was estimated at 1,060 L/h (interindividual variability 33.6%) and volume of distribution at 200 L; age, body size, race and health status were not related to the PK parameters within the studied range, and the fraction absorbed by the first-order process was 13.1% higher on day 14 than day 1 [4]. A companion PK/PD analysis of 41 subjects modelled GH secretion as “episodic”, stimulated for a finite duration, and used that GH model to drive IGF-1. No covariates were significantly associated with GH or IGF-1 parameters, and predictive checks supported the sequential model [5]. These are modelling papers built on small Phase 1 sets; they describe a specific clinical formulation and do not transfer to other materials.
Pulsatility rather than a flat GH signal
A key pharmacological argument for a GHRH analogue is that it works through the pituitary and its normal feedback, so GH remains pulsatile. Stanley and colleagues tested this in 13 healthy men studied at baseline, after 2 weeks of once-daily tesamorelin and after 2 weeks of withdrawal, using overnight frequent blood sampling. Mean overnight GH rose (P = 0.004), as did log GH peak area (P = 0.001) and basal GH secretion (P = 0.008), and IGF-I increased substantially (P < 0.0001); neither fasting glucose (P = 0.93) nor clamp-measured insulin-stimulated glucose uptake (P = 0.61) changed significantly [6]. A secondary analysis from the same 2-week design found total adiponectin associated with peak GH area and basal secretion, but short-term augmentation of GH pulsatility did not change total or high-molecular-weight adiponectin [7]. Earlier reviews of GHRH and secretagogues in normal ageing framed this as a way to probe the somatotropic axis while preserving feedback, while noting how little long-term data existed [8].
Interaction and downstream signals
Because GH can influence hepatic enzyme expression, a clinical pharmacology study examined CYP3A. In two randomised crossover studies in healthy volunteers, simvastatin AUC and Cmax ratios with and without tesamorelin stayed within the usual 80-125% no-effect range; for ritonavir, AUCs met that range but the lower confidence limit for Cmax was 74.8%, suggesting a decreased rate of exposure [9]. Further downstream, a 12-month randomised trial in people with HIV and fatty liver disease used proteomics and liver transcriptomics: circulating concentrations of 13 immune-related proteins decreased versus placebo, and none increased [10]. Reviews of the pivotal 26-week trials emphasise that visceral-fat changes reversed after discontinuation, consistent with an effect that depends on continued axis stimulation [3,11].
What remains open
- Small PK sets. Population models rest on 38-41 Phase 1 participants [4,5].
- Short pulsatility studies. Frequent-sampling data cover 2 weeks in 13 men [6,7].
- Feedback over longer periods. Whether pulsatile patterns and IGF-1 responses stay stable over months has been inferred mainly from efficacy trials rather than from repeated frequent-sampling studies [3,6].
- Covariates. No covariates were identified in the PK or PK/PD models, but the covariate ranges studied were narrow [4,5].
- Mechanism versus material. Plasma-stability findings describe the characterised TH9507 peptide, not any commercial research vial [1].
Tesamorelin 5mg at PurixLab
Tesamorelin 5mg: a labelled lyophilized research vial with 5mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tesamorelin-5mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Ferdinandi ES, Brazeau P, High K, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007;100(1):49-58. PubMed 17214611 · doi:10.1111/j.1742-7843.2007.00008.x
- Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin. Nat Rev Drug Discov. 2011;10(2):95-6. PubMed 21283099 · doi:10.1038/nrd3362
- Dhillon S. Spotlight on tesamorelin in HIV-associated lipodystrophy. BioDrugs. 2011;25(6):405-8. PubMed 22050344 · doi:10.2165/11208290-000000000-00000
- González-Sales M, Barrière O, Tremblay PO, et al. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin Pharmacokinet. 2015;54(3):285-94. PubMed 25358450 · doi:10.1007/s40262-014-0202-x
- González-Sales M, Barrière O, Tremblay PO, et al. Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects. J Pharmacokinet Pharmacodyn. 2015;42(3):287-99. PubMed 25895899 · doi:10.1007/s10928-015-9416-2
- Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-8. PubMed 20943777 · PMC3038486 · doi:10.1210/jc.2010-1587
- Makimura H, Stanley TL, Chen CY, et al. Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor. Growth Horm IGF Res. 2011;21(3):155-9. PubMed 21531600 · PMC3112279 · doi:10.1016/j.ghir.2011.03.009
- Merriam GR, Schwartz RS, Vitiello MV. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003;22(1):41-8. PubMed 14610297 · doi:10.1385/ENDO:22:1:41
- Teng S, Potvin D, Mamputu JC, et al. Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers. Clin Pharmacol Drug Dev. 2013;2(3):237-45. PubMed 27121785 · doi:10.1002/cpdd.27
- Stanley TL, Fourman LT, Wong LP, et al. Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease. Clin Infect Dis. 2021;73(4):621-630. PubMed 33852720 · PMC8366828 · doi:10.1093/cid/ciab019
- Falutz J. Tesamorelin: a novel therapeutic option for HIV/HAART-associated increased visceral adipose tissue. Drugs Today (Barc). 2011;47(6):419-30. PubMed 21695284 · doi:10.1358/dot.2011.47.6.1603439